openPR Logo
Press release

B-cell Maturation Antigen (BCMA) Targeted Therapies Market Growth, Analysis, and Industry Forecast till 2025

08-07-2018 03:58 PM CET | Health & Medicine

Press release from: CMI Research

B-cell Maturation Antigen (BCMA) Targeted Therapies Market

The Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, by product type (CAR-T cell, bispecific antibodies, and antibody drug conjugates), and by indication (acute lymphoblastic leukemia, and multiple myeloma) has potential products in pipeline, as highlighted in a new report published by Coherent Market Insights. Increasing number of BCMA targeted therapies in pipeline and increasing prevalence of multiple myeloma are expected to favor growth of the B-cell maturation antigen (BCMA) targeted therapies market worldwide.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/190

Increasing recurrence of multiple myeloma has been a major obstacle. According to the National Cancer Institute, in 2016, around 75,000 patients globally were recorded to be suffering from relapsed or refractory multiple myeloma, with a relative survival rate of 5 years. According to American Cancer Society, as of 2017, around 30,280 multiple myeloma cases are estimated to be diagnosed, out of which around 12,590 deaths are estimated to occur. Multiple myeloma (MM) is the second most common hematological malignancy in the U.S. and European countries. According to American Cancer Society, in the U.S. the lifetime risk of contracting multiple myeloma is 1 in 143 (0.7%). B-cell maturation antigen (BCMA), is a cell surface protein that is expressed on the malignant plasma cells.

Browse through 130 Pages and an in-depth TOC on ‘B-cell Maturation Antigen (BCMA) Targeted Therapies, by Product type (Antibody Drug Conjugates, CAR-T Cells, and Bispecific Antibodies), by Indication (Acute Lymphoblastic Leukemia and Multiple Myeloma), and by Region

Request Sample Copy Of This Report: https://www.coherentmarketinsights.com/insight/request-sample/190

According to the Cancer Research U.K., as of 2014, myeloma is estimated to be the 18th most common cancer in the U.K., with an estimated 5,500 new cases of multiple myeloma, reported around 15 new cases every day. Incidence rates for myeloma are projected to rise by 11% or 12 cases per 100,000 people by 2035. According to the National Center for Biotechnology Information, 2014, multiple myeloma represents 8.2% of all blood cancers in Africa.

Market players are actively investing in research and development of novel multiple myeloma therapies to develop alternatives for existing drugs. These therapies include chimeric antigen receptor T cells, antibody-drug conjugate, and bispecific antibodies. Preclinical and clinical trial results on these therapies have demonstrated potential benefits.

Key Takeaways of the Market:

According to the American Society of Clinical Oncology (ASCO), in 2016, multiple myeloma was the second most common blood cancer, after non-Hodgkin lymphoma, accounting for 1% of all kinds of malignancies globally, with 70 years being the median age of diagnosis

As there are no treatment option available for patients with recurrent cancer, development of therapy to treat relapsed and/or refractory multiple myeloma is expected to provide market players with lucrative opportunities

Some of the major players involved in the development of B-cell maturation antigen (BCMA) targeted therapies market are Celgene Corporation, GlaxoSmithKline plc, Novartis AG, Juno Therapeutics, Gilead Sciences. Inc., Amgen Inc., Affimed N.V, Poseida Therapeutics, Inc., and Autolus Ltd.

Ask for customization: https://www.coherentmarketinsights.com/insight/request-customization/190

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154
#3200

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release B-cell Maturation Antigen (BCMA) Targeted Therapies Market Growth, Analysis, and Industry Forecast till 2025 here

News-ID: 1167132 • Views:

More Releases from CMI Research

Complete guide to Eosinophilic Esophagitis Market 2023: Expanding due to immune system rapid growth | Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline
Complete guide to Eosinophilic Esophagitis Market 2023: Expanding due to immune …
Eosinophilic Esophagitis (EoE) is a chronic inflammatory condition of the esophagus. It is characterized by the accumulation of a type of white blood cells called eosinophils in the lining of the esophagus. EoE can cause a range of symptoms, including difficulty swallowing, food impaction, chest pain, and heartburn. Steroids are the primary treatment option for EoE. They help control inflammation and reduce the number of eosinophils in the esophagus. Topical steroids
A complete guide to Adoptive Cell Therapy Market 2023: growing demand for personalized medicine rapid growth | Gilead Sciences, Inc., Castle Creek Biosciences, Inc., Lineage Cell Therapeutics
A complete guide to Adoptive Cell Therapy Market 2023: growing demand for person …
Adoptive cell therapy (ACT) is a form of immunotherapy that involves the genetic modification of T cells to enhance their cancer-fighting capabilities. This treatment has shown promising results in the treatment of several types of cancer and is expected to become a major player in the oncology market in the coming years. The global adoptive cell therapy market size was valued at USD 1.12 billion in 2021 and is projected to
A complete guide to the TCV Vaccines Market 2023: market size, growth trends, key drivers and and future outlook 2030 | GlaxoSmithKline PLC, Sanofi SA, Bharat Biotech
A complete guide to the TCV Vaccines Market 2023: market size, growth trends, ke …
Conjugate vaccine (Vi-TT) consists of Vi antigen that is coupled to a carrier protein. In this vaccine, polysaccharide is attached to a more complex protein. In infants, these cells can effectively develop immune protection against pathogens. Polysaccharides are weaker by itself, however, by binding to a protein carrier, polysaccharides can enter into important parts of the immune system with ease and can get more easily noticed by the immunity system
A complete guide to Corporate Wellness Market 2023: Market size, growth trends, key drivers and challenges, and future outlook 2030 | Wellness Corporate Solutions, ComPsych Corporation, United Health Group
A complete guide to Corporate Wellness Market 2023: Market size, growth trends, …
The corporate wellness market has been gaining popularity over the years as more companies recognize the importance of keeping their employees healthy and productive. Corporate wellness programs are designed to improve the overall health and well-being of employees by providing them with resources and support to manage their physical and mental health. The corporate wellness market is expected to grow significantly from 2023-2030. According to a report by Coherent Market Insights,

All 5 Releases


More Releases for BCMA

BCMA/CD3 Bispecific Antibody Market Share Driven by Breakthroughs in Targeted Im …
BCMA/CD3 Bispecific Antibody Market BCMA/CD3 targeted drug is a bispecific antibody drug used to treat multiple myeloma. It simultaneously targets B cell maturation antigen (BCMA) and CD3 molecules on the surface of T cells, directing T cells to cancer cells, thereby enhancing the killing effect on cancer cells. The global BCMA/CD3 Bispecific Antibody market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a
Targeting Tomorrow: Advancements and Opportunities in the BCMA-Targeted Therapy …
In today's dynamic global economy, the B cell maturation antigen targeted therapy market is emerging as a beacon of opportunity and innovation. With rapid technological advancements, evolving consumer demands, and proactive government policies shaping the landscape, this sector is setting the stage for transformative change. Our in-depth analysis delves into historical market trends, current dynamics, and future projections, providing industry leaders, investors, and decision-makers with the strategic insights needed to
Global B-Cell Maturation Antigen (BCMA) Targeted Therapies Market - Opportunitie …
Dhirtek Business Research and Consulting recently released its most comprehensive research report to date on the global b-cell maturation antigen (bcma) targeted therapies market. Through extensive research, analysts have provided an extensive look into the market's drivers and restraints, and identified the key milestones and trends that will shape its future. Primary and secondary research methods were used to create this in-depth report. Through the analysis of the research, Dhirtek was
Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market and Clinical Tri …
Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market and Clinical Trials Insight 2026 Report Analysis and Data Highlights: * Research Methodology * Global and Regional Market Analysis * Global BCMA Targeted Drugs Market Opportunity Assessment: > USD 4 Billion * Market and Drug Sales Insight 2020 Till 2026 * Approved Drug In Market: 2 Drugs * Approved BCMA Targeted Drugs Patent, Price and Sales insight 2020 Till 2026 * Future Market Assessment By Indication Till 2026 *
B-Cell Maturation Antigen (BCMA) Targeted Therapies Market 2022 | Detailed Repor …
The B-Cell Maturation Antigen (BCMA) Targeted Therapies research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and engagement. The competitive landscape is studied here in terms of product range, strategies, and prospects of the market’s key players. Furthermore, the report offers insightful market data and information
B-cell Maturation Antigen (BCMA) Targeted Therapies Market - Insights, Size, Ana …
The Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, by product type (CAR-T cell, bispecific antibodies, and antibody drug conjugates), and by indication (acute lymphoblastic leukemia, and multiple myeloma) has potential products in pipeline, as highlighted in a new report published by Coherent Market Insights. Increasing number of BCMA targeted therapies in pipeline and increasing prevalence of multiple myeloma are expected to favor growth of the B-cell maturation antigen (BCMA)